The Federal Trade Commission has initiated formal administrative proceedings against the nation's three dominant pharmacy benefit managers (PBMs)—Caremark Rx (CVS Health), Express Scripts (Cigna Group), and OptumRx (UnitedHealth Group)—alleging they orchestrated an anticompetitive rebate system that artificially inflated the list prices of life-saving insulin medications.

The regulatory action, which also names affiliated group purchasing organizations including Zinc Health Services and Ascent Health Services, targets corporate middlemen that collectively process approximately 80% of all prescription drug claims across the United States. Regulators charge that these intermediaries systematically distorted pharmaceutical distribution to extract billions of dollars in manufacturer rebates.

Perverse Rebate Incentives and Formulary Gatekeeping

According to the FTC's legal filing, the Big Three PBMs exploited their market leverage to demand escalating rebate payments from pharmaceutical manufacturers in exchange for preferred formulary placement. Drugmakers that offered low-list-price insulins were systematically shut out of commercial formularies because lower sticker prices yielded smaller rebate kickbacks for the PBMs and their purchasing units.

Consequently, pharmaceutical giants were incentivized to artificially raise the list price of widely prescribed insulins—such as Humalog, Novolog, and Lantus—by hundreds of percent. While manufacturer net prices often fell or remained flat after rebates were paid to PBMs, patients whose insurance required high deductibles or percentage-based coinsurance were forced to pay out-of-pocket charges calculated against the inflated list price.

“Millions of Americans rely on insulin to survive every day, yet the Big Three PBMs have weaponized their gatekeeper power to enrich themselves while forcing vulnerable patients to ration care.”

Exclusion of Affordable Biosimilars and Patient Cost Burdens

The complaint specifically highlights how PBMs resisted incorporating authorized generics and biosimilar insulins launched at discounts of up to 65% to 70% below brand-name list prices. By steering insured members away from affordable generic options toward high-cost branded alternatives, the PBMs allegedly prioritized their own commercial bottom lines over consumer financial welfare and public health.

The Pharmaceutical Care Management Association, representing the PBM industry, disputed the allegations, arguing that PBMs serve as the primary market check against unrestricted drugmaker pricing and that negotiated rebates are overwhelmingly passed through to employer health plan sponsors to lower employee premiums. Legal experts predict the lawsuit will trigger widespread scrutiny of pharmaceutical supply chain transparency.

Sources

FTC PBMs Insulin Healthcare Pharmaceuticals Antitrust Drug Pricing